Rakuten Medical to Present New Data of Alluminox™ Treatment using ASP-1929 in Combination with anti-PD-1 at AHNS 2023

On May 12, 2023 Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, reported that the abstract ‘Safety and efficacy findings from a phase 1b/2 open-label study of a novel combination of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma’ has been selected for a podium presentation at this year’s American Head and Neck Society (AHNS) 11th International Conference on Head and Neck Cancer (AHNS 2023) (Press release, Rakuten Medical, MAY 12, 2023, View Source [SID1234631606]). AHNS is the single largest organization in North America for the advancement of research and education in head and neck oncology. AHNS 2023 will be held from July 8th to 12th, 2023 in Montreal, Canada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will for the first time showcase topline safety and efficacy findings from an open-label Phase 1b/2 study (ASP-1929-181/ClinicalTrials.gov Identifier: NCT04305795) of Alluminox treatment (photoimmunotherapy) using ASP-1929 in combination with anti-PD-1 therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Rakuten Medical will also have a booth in the exhibit hall. In addition, several presentations involving Alluminox treatment (photoimmunotherapy) have also been selected for presentation at AHNS 2023.

Details on Rakuten Medical activities throughout AHNS 2023 are below:

Podium Presentation

Abstract Title: Safety and efficacy findings from a phase 1b/2 open-label study of a novel combination of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma
Session Name: Proffered Papers 21 – Immunotherapy Session 2
Session Date: Monday, July 10th, 2023
Session Time: 2:00 p.m. – 3:30 p.m. (approx. 10 mis for our presentation)
Presenter: Ann M. Gillenwater, Professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center
Program Number: S252
Rakuten Medical Booth

Location: Exhibit Hall
Exhibit Date: Sunday – Tuesday, July 9th – 11th, 2023
* Rakuten Medical’s therapies based on Alluminox platform are investigational outside of Japan.